Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • ajetjock ajetjock Dec 20, 2013 8:43 AM Flag

    Great news folks ! Looks like SNTA is gearing up for a...DEAL.

    Synta Announces Appointment of Steven Bernitz as Senior Vice President, Corporate Development
    Business Wire Synta Pharmaceuticals Corp.
    5 minutes ago

    LEXINGTON, Mass.--(BUSINESS WIRE)--

    Synta Pharmaceuticals Corp. (SNTA) today announced the appointment of Steven Bernitz as Senior Vice President, Corporate Development. Mr. Bernitz brings over 20 years' experience in corporate strategy, business leadership and transactional experience in life sciences.

    Prior to Synta, Mr. Bernitz was a General Partner and Head of the BioPharma Practice at Extera Partners, a business development advisory firm. At Extera, he led numerous business development and strategy initiatives for development stage companies and their investors, principally in oncology, autoimmune and orphan diseases.

    Prior to joining Extera in 2010, Mr. Bernitz was Chief Business Officer at Concert Pharmaceuticals where he led Concert’s $1 billion deal with GlaxoSmithKline, and prior to Concert he was Senior Vice President, Business and Product Development at Coley Pharmaceutical Group, where he led numerous transactions including Coley’s $600 million oncology deal with Pfizer. Mr. Bernitz has also been CEO of Histogenics and Organogenesis, both cell therapy companies, and earlier in his career was with Merck Vaccines and McKinsey & Co.

    “Steve has tremendous deal experience, as is clear from his track record, which will be valuable in realizing the potential of both our ganetespib and HDC programs,” said Safi Bahcall, President and CEO, Synta. “His wealth of diverse business experiences and insights make him an excellent addition to our executive team, as we manage a growing pipeline and an increasing number of important strategic and operational choices.”

    “Synta has the potential to make a tremendous difference in the lives of cancer patients,” said Mr. Bernitz. “Both ganetespib and the HDC platform represent innovative new treatment approaches that can transform standard of care. I am excited to join the

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SNTA
2.14-0.03(-1.38%)May 29 4:00 PMEDT